Benefits of biomarkers
in NMIBC monitoring

Urinary biomarker tests can detect bladder cancer recurrence and optimise clinical decision-making.

Recent developments in medical diagnostics aim to significantly reduce the number and frequency of invasive procedures, alleviating the heavy burden for the patient and physician.

Due to the high frequency of recurrence, NMBIC surveillance is crucial. The current guidelines recommend cystoscopy and cytology, although many high-risk (carcinoma in situ) tumours are missed and the regular invasive procedures pose a significant burden for the patient.
This is where reliable urinary biomarkers come into play.
A simple urine sample is sufficient to reveal vital information on NMIBC recurrence. The ideal biomarker test is an excellent aid to cystoscopy and can safely reduce the number of hospital visits.

Curious as to how these tests work? View our freely available slide resources and brochures for all you need to know on NMIBC biomarkers.

Benefits of biomarkers
in NMIBC monitoring

Urinary biomarker tests can detect bladder cancer recurrence and optimise clinical decision-making.

Recent developments in medical diagnostics aim to significantly reduce the number and frequency of invasive procedures, alleviating the heavy burden for the patient and physician.

Due to the high frequency of recurrence, NMBIC surveillance is crucial. The current guidelines recommend cystoscopy and cytology, although many high-risk (carcinoma in situ) tumours are missed and the regular invasive procedures pose a significant burden for the patient.
This is where reliable urinary biomarkers come into play.
A simple urine sample is sufficient to reveal vital information on NMIBC recurrence. The ideal biomarker test is an excellent aid to cystoscopy and can safely reduce the number of hospital visits.

Curious as to how these tests work? View our freely available slide resources and brochures for all you need to know on NMIBC biomarkers.

02

Use the Bladder EpiCheck® test in your clinical practice >>

Testimonials

Prof. Fred Witjes, Radboud UMC
Nijmegen, the Netherlands

Rob de Vos
Living with high grade NMIBC

Gerard Lensvelt
The burden of Living with bladder cancer

Keep your NMIBC patients safe during COVID-19, with Bladder EpiCheck

Editorial board

Jørgen Bjerggaard Jensen

Aarhus University Hospital
Aarhus, Denmark

Conflict of interest

[26 May 2020]
Proctor for Intuitive Surgery;
Member of Advisory Boards at Ferring and Cepheid;
Speaker for Medac and Olympus;
Research collaboration with Photocure ASA, Medac, Roche, Ferring, Karl Storz, Olympus, Intuitive Surgery, Astellas, AstraZeneca, Cepheid, and EpiCheck;
Patent holder of the JB-One en bloc retriever;
Editorial board member of BCaMonitor.org.

Hugh Mostafid

Royal Surrey County Hospital
Guildford, UK
 
Conflict of interest

[26 May 2020]
Cepheid Advisory Board;
Editorial board member of BCaMonitor.org.

Joost Boormans

Erasmus MC Cancer Institute
Rotterdam, the Netherlands

Conflict of interest

[26 May 2020]
Consultancy: MSD, Janssen Pharmaceuticals, MML medical;
Speaker’s fee: Ipsen;
Research funding: Decipher Biosciences;
Editorial board member of BCaMonitor.org.

Morgan Rouprêt

Pitié-Salpêtrière Hospital –
AP-HP Sorbonne University
Paris, France

Conflict of interest

[29 June 2020]
Consultant/Advisory Board for Nucleix, Astellas, Ipsen, Janssen, Intuitive, AstraZeneca, Ferring, Arquer Diagnostics, Roche, MSD;
Editorial board member of BCaMonitor.org.

Paolo Gontero

San Giovanni Battista (Molinette) Hospital – University of Turin School of Medicine
Turin, Italy

Conflict of interest

[7 July 2020]
Advisory Board, Recipient of Research Grants, Trial Investigator or Lecturer for Ipsen, Astellas, Ferring, Arquer Diagnostics, Cepheid, Medacs and Janssen;
Editorial board member of BCaMonitor.org.

Brochure & slide resource

Stay informed about new releases in the field